In summary, the serum concentration of HE4, a novel biomarker for ovarian cancer, was not increased in patients with ovarian endometrioma or any other types of endometriosis, whereas the serum CA125 concentration was increased in patients with advanced endometriosis. Here, WFDC2 is linked to endometriosis.